Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immunogenicity and Safety of Concomitant Inoculation of Recombinant Human Papillomavirus Bivalent (Types 16,18) Vaccine (Escherichia Coli) and Measles Mumps and Rubella Combined Vaccine, Live

NCT05279248 is registered in ClinicalTrials.gov with Zhejiang Provincial Center for Disease Control and Prevention as lead sponsor.

NCT NCT05279248
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05279248 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immunogenicity and Safety of Concomitant Inoculation of Recombinant Human Papillomavirus Bivalent (Types 16,18) Vaccine (Escherichia Coli) and Measles Mumps and Rubella Combined Vaccine, Live
Lead sponsor
Zhejiang Provincial Center for Disease Control and Prevention
Phase
Phase 4
Overall status
Unknown status
Start date
August 25, 2021
Completion date
June 20, 2023
Enrollment
300 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

human papilloma virus infection type 16, human papilloma virus infection type 18, measles, mumps, rubella